Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab plus platinum-based chemotherapy for newly diagnosed thymic carcinoma
ChiCTR2300076314Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of penpulimab in thymic carcinoma (TC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
penpulimab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2300076314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076314.